SI2459208T1 - Sredstva za znižanje nivoja obščitničnega hormona - Google Patents

Sredstva za znižanje nivoja obščitničnega hormona

Info

Publication number
SI2459208T1
SI2459208T1 SI201031337A SI201031337A SI2459208T1 SI 2459208 T1 SI2459208 T1 SI 2459208T1 SI 201031337 A SI201031337 A SI 201031337A SI 201031337 A SI201031337 A SI 201031337A SI 2459208 T1 SI2459208 T1 SI 2459208T1
Authority
SI
Slovenia
Prior art keywords
therapeutic agents
parathyroid hormone
hormone levels
reducing parathyroid
reducing
Prior art date
Application number
SI201031337A
Other languages
English (en)
Slovenian (sl)
Inventor
Felix Karim
Amos Baruch
Derek Maclean
Kanad Das
Qun Yin
Original Assignee
Kai Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43527590&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2459208(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kai Pharmaceuticals, Inc. filed Critical Kai Pharmaceuticals, Inc.
Publication of SI2459208T1 publication Critical patent/SI2459208T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SI201031337A 2009-07-29 2010-07-29 Sredstva za znižanje nivoja obščitničnega hormona SI2459208T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22969509P 2009-07-29 2009-07-29
US25581609P 2009-10-28 2009-10-28
US31363510P 2010-03-12 2010-03-12
EP10805078.2A EP2459208B1 (en) 2009-07-29 2010-07-29 Therapeutic agents for reducing parathyroid hormone levels
PCT/US2010/043792 WO2011014707A2 (en) 2009-07-29 2010-07-29 Therapeutic agents for reducing parathyroid hormone levels

Publications (1)

Publication Number Publication Date
SI2459208T1 true SI2459208T1 (sl) 2017-04-26

Family

ID=43527590

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201031337A SI2459208T1 (sl) 2009-07-29 2010-07-29 Sredstva za znižanje nivoja obščitničnega hormona
SI201031894T SI3192520T1 (sl) 2009-07-29 2010-07-29 Terapevtska sredstva za zniževanje ravni paratiroidnega hormona

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI201031894T SI3192520T1 (sl) 2009-07-29 2010-07-29 Terapevtska sredstva za zniževanje ravni paratiroidnega hormona

Country Status (29)

Country Link
US (11) US8999932B2 (enExample)
EP (5) EP3539555B1 (enExample)
JP (3) JP5270799B2 (enExample)
KR (1) KR101781841B1 (enExample)
CN (2) CN102711789B (enExample)
AU (1) AU2010278897B2 (enExample)
BR (1) BR112012002143B8 (enExample)
CA (1) CA2769525C (enExample)
CY (3) CY1118388T1 (enExample)
DK (2) DK3192520T3 (enExample)
ES (2) ES2607954T3 (enExample)
FR (1) FR17C1009I2 (enExample)
HR (2) HRP20161614T1 (enExample)
HU (3) HUE043838T2 (enExample)
IL (1) IL217749A (enExample)
LT (3) LT3192520T (enExample)
LU (1) LUC00008I2 (enExample)
MX (1) MX2012001213A (enExample)
NO (1) NO2017021I1 (enExample)
NZ (1) NZ597922A (enExample)
PL (2) PL3192520T3 (enExample)
PT (2) PT3192520T (enExample)
RU (1) RU2557654C3 (enExample)
SG (2) SG10201406921SA (enExample)
SI (2) SI2459208T1 (enExample)
SM (3) SMT201700014B (enExample)
TW (1) TWI520744B (enExample)
WO (1) WO2011014707A2 (enExample)
ZA (1) ZA201200726B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8987200B2 (en) * 2006-11-16 2015-03-24 Kai Pharmaceuticals, Inc. Polycationic calcium modulator peptides for the treatment of hyperparathyroidism and hypercalcemic disorders
EP3539555B1 (en) * 2009-07-29 2020-12-30 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels
KR101493717B1 (ko) 2010-03-04 2015-02-16 아지노모토 가부시키가이샤 알킬아민 유도체
JP5761173B2 (ja) 2010-03-04 2015-08-12 味の素株式会社 糖尿病又は肥満症の予防又は治療剤
EP2551262A4 (en) 2010-03-24 2014-01-15 Ajinomoto Kk GLUTAMATE DERIVATIVES OR SALTS THEREOF
JPWO2011126099A1 (ja) 2010-04-02 2013-07-11 味の素株式会社 糖尿病又は肥満症の予防又は治療剤
LT2717896T (lt) * 2011-06-08 2017-02-27 Kai Pharmaceuticals, Inc. Terapiniai agentai, skirti fosforo koncentracijos serume reguliavimui
EP2776129B2 (en) * 2011-11-10 2020-06-17 Kai Pharmaceuticals, Inc. Compositions for use in the treatment of chronic kidney disease-mineral bone disorder characterized by soft tissue calcification
EP2872160A4 (en) * 2012-04-17 2015-11-25 Univ Brown NERVO-PROTECTING COMPOSITION AND USE METHOD
US20200354428A9 (en) 2013-06-23 2020-11-12 Wisconsin Alumni Research Foundation Analogues of parathyroid hormone (1-34) that function as agonists of the parathyroid hormone receptor-1 and display modified activity profiles
PE20210413A1 (es) 2013-06-28 2021-03-04 Amgen Inc Formulacion liquida estable que comprende etelcalcetida (amg416), un agente tamponante y agente de tonicidad
DK3126373T3 (da) * 2014-04-03 2020-05-04 Amgen Inc Fremgangsmåde til fremstilling af amg 416
CN105504012A (zh) * 2014-09-30 2016-04-20 深圳翰宇药业股份有限公司 一种多肽的制备方法
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
US10858389B2 (en) 2015-03-26 2020-12-08 Amgen Inc. Solution phase method for preparing etelcalcetide
US9336841B1 (en) * 2015-04-16 2016-05-10 Taiwan Semiconductor Manufacturing Co., Ltd. Pipeline register with data alignment therein
CN106928321B (zh) * 2015-12-31 2019-07-26 深圳翰宇药业股份有限公司 一种合成Etelcalcetide的方法
CN106928320B (zh) 2015-12-31 2021-01-15 深圳翰宇药业股份有限公司 一种合成Etelcalcetide的方法
WO2018044468A1 (en) * 2016-08-30 2018-03-08 Wisconsin Alumni Research Foundation COMBINATION OF LOW DOSE 2-METHYLENE-19-NOR-(20S)-1α, 25-DIHYDROXYVITAMIN D3 AND CALCIMIMETICS TO TREAT SECONDARY HYPERPARATHYROIDISM
US20200261549A1 (en) * 2017-11-07 2020-08-20 Alphacore Pharma Llc Methods of treating and protecting against cardiac disease, cardiovascular disease and related conditions and symptoms
WO2019124411A1 (ja) 2017-12-20 2019-06-27 Ｅａファーマ株式会社 維持透析下の二次性副甲状腺機能亢進症の予防または治療用医薬組成物
KR101933685B1 (ko) * 2018-06-29 2018-12-28 주식회사 에스알바이오텍 약물이 코팅된 마이크로 니들 및 이의 제조방법
KR20210124958A (ko) * 2018-11-02 2021-10-15 앰퍼샌드 바이오파마슈티컬스, 인코포레이티드 국소적으로 적용되는 완충제(buffers)를 사용하는 양이온 과부하 및 전해질 불균형의 위험 가능성 관리를 위한 제형 및 방법
WO2020204117A1 (ja) 2019-04-03 2020-10-08 Ｅａファーマ株式会社 安定性の良好な医薬組成物
BR112022011127A2 (pt) * 2019-12-09 2022-08-23 Beijing Tuo Jie Biopharmaceutical Co Ltd Composto agonista do receptor de detecção de cálcio e aplicação do mesmo
WO2021226064A1 (en) * 2020-05-04 2021-11-11 University Of Louisville Research Foundation, Inc. Artificial intelligence-based systems and methods for dosing of pharmacologic agents
KR20230066044A (ko) * 2020-09-10 2023-05-12 샨시 마이콧 테크놀로지 컴퍼니 리미티드 이중특이적 융합 폴리펩타이드 화합물
US11359134B2 (en) 2020-10-19 2022-06-14 Saudi Arabian Oil Company Treatment fluids and methods for recovering hydrocarbons from a subterranean formation
WO2022257940A1 (zh) * 2021-06-08 2022-12-15 北京拓界生物医药科技有限公司 钙敏感受体激动剂化合物的盐酸盐及药物组合物和其应用
CN117295510A (zh) * 2021-06-08 2023-12-26 北京拓界生物医药科技有限公司 一种钙敏感受体激动剂的组合物及其应用
US12233115B2 (en) 2022-09-30 2025-02-25 Extend Biosciences, Inc. Long-acting parathyroid hormone
WO2025054169A1 (en) * 2023-09-05 2025-03-13 Wake Forest University Health Sciences Compositions and methods for topical treatment

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602116A (en) 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
US5869473A (en) 1988-08-02 1999-02-09 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US5246925A (en) * 1989-03-09 1993-09-21 Wisconsin Alumni Research Foundation 19-nor-vitamin D compounds for use in treating hyperparathyroidism
CA1333616C (en) * 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
WO1992008476A1 (en) 1990-11-07 1992-05-29 The Scripps Research Institute Peptides that inhibit platelet binding of adhesion molecules
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5814603A (en) * 1992-06-12 1998-09-29 Affymax Technologies N.V. Compounds with PTH activity
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
CA2145214A1 (en) 1995-02-28 1996-08-29 Rick E. Preddie Agents for pre-symptomatic diagnosis, prevention and cure huntington's disease (hd) in humans
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US5688489A (en) * 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
ATE304020T1 (de) 1996-07-31 2005-09-15 Gen Hospital Corp Parathyroidhormon-verwandthe peptidanaloge
US5895368A (en) * 1996-09-23 1999-04-20 Medisystems Technology Corporation Blood set priming method and apparatus
WO1998017299A1 (en) * 1996-10-18 1998-04-30 The Board Of Trustees Of The Leland Stanford Junior University Isozyme-specific activators of protein kinase c, methods and compositions
US5955431A (en) * 1997-02-05 1999-09-21 Brigham And Women's Hospital, Inc. Mast cell protease peptide inhibitors
PL336803A1 (en) 1997-05-14 2000-07-17 Rhone Poulenc Rorer Pharma Analogues of peptidic parathyroid hormone
BR9809138A (pt) * 1997-05-21 2001-08-28 Trustees For The Leland Stanfo Conjugado e método para aumentar o transporte de um composto selecionado atravessando uma membrana biológica
US6258774B1 (en) 1998-03-19 2001-07-10 University Of Medicine And Dentistry Of New Jersey Carrier for in vivo delivery of a therapeutic agent
US7399489B2 (en) 1999-01-14 2008-07-15 Amylin Pharmaceuticals, Inc. Exendin analog formulations
JP2000336099A (ja) * 1999-05-27 2000-12-05 Sekisui Chem Co Ltd ペプチド及びｃ型肝炎抗体検出用試薬
US6274169B1 (en) 1999-08-02 2001-08-14 Abbott Laboratories Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol
US6051567A (en) * 1999-08-02 2000-04-18 Abbott Laboratories Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol
US20020068342A1 (en) * 2000-02-09 2002-06-06 Rami Khosravi Novel nucleic acid and amino acid sequences and novel variants of alternative splicing
EP1301479A2 (en) 2000-07-18 2003-04-16 Bone Care International, Inc. STABILIZED 1$g(a)-HYDROXY VITAMIN D
DE10041126A1 (de) * 2000-08-22 2002-04-04 Aventis Res & Tech Gmbh & Co DNA-bindende Peptiddomänen und ein Verfahren zur Bereitstellung solcher Domänen
US20080249016A1 (en) * 2000-09-18 2008-10-09 Sanos Bioscience A/S Use of GLP-2 in a combination treatment for bone-related disorders
US20020168354A1 (en) * 2000-11-10 2002-11-14 Daria Mochly-Rosen psiepsilonRack peptide composition and method for protection against tissue damage due to ischemia
WO2002057413A2 (en) * 2001-01-18 2002-07-25 The Board Of Trustees Of The Leland Stanford Junior University Peptides for activation and inhibition of delta pkc
WO2002062396A2 (en) 2001-02-08 2002-08-15 University Of Medicine And Dentistry Of New Jersey Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents using polymer conjugates
US20030036627A1 (en) * 2001-02-16 2003-02-20 Montelaro Ronald C. Virus derived antimicrobial peptides
WO2002070547A1 (en) 2001-02-23 2002-09-12 Polyphor Ltd. Template-fixed peptidomimetics with antimicrobial activity
WO2003013543A1 (en) 2001-08-08 2003-02-20 Genomed, Llc Treatment or prevention of acute renal failure
US6790833B2 (en) * 2001-08-08 2004-09-14 The Research Foundation Of The State University Of New York Antifungal and antibacterial agents
US7060023B2 (en) 2001-09-25 2006-06-13 The Foundry Inc. Pericardium reinforcing devices and methods of using them
US7037897B2 (en) * 2001-10-31 2006-05-02 Abbott Laboratories TRI-, TETRA-, and penta-peptides having antiangiogenic activity
JP2005287302A (ja) 2002-04-03 2005-10-20 Haruhiko Fujiwara ポリペプチドの架橋方法
EP1576141A4 (en) * 2002-05-14 2006-03-22 Bristol Myers Squibb Co NEW HUMAN G-PROTEIN-COUPLED RECEPTORS CODING POLYNUCLEOTIDE AND SPLEISS VARIANTS THEREOF
WO2005049647A2 (en) 2003-11-05 2005-06-02 Pevion Biotech Ltd. Compositions comprising melittin-derved peptides and methods for the potentiation of immune responses against target antigens
KR20070004571A (ko) 2003-12-11 2007-01-09 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 단백질 키나제 ｃ의 동종효소-특이적 길항제
US7939634B2 (en) 2004-01-27 2011-05-10 Compugen Ltd. Polynucleotides encoding polypeptides and methods using same
WO2006015005A2 (en) * 2004-07-27 2006-02-09 Genzyme Corporation Use of thyrotropin for regeneration of bone
US7265092B2 (en) * 2004-09-30 2007-09-04 Kai Pharmaceuticals, Inc. Pharmaceutical formulation
DE102005013846A1 (de) 2005-03-24 2006-10-05 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
KR100687932B1 (ko) * 2005-08-09 2007-02-27 삼성전자주식회사 영상표시장치 및 영상표시방법
EP1937064A4 (en) * 2005-08-30 2009-09-16 Acologix Inc REGULATION OF MINERALS AND SKELETAL METABOLISM
US8987200B2 (en) * 2006-11-16 2015-03-24 Kai Pharmaceuticals, Inc. Polycationic calcium modulator peptides for the treatment of hyperparathyroidism and hypercalcemic disorders
WO2008089491A2 (en) 2007-01-19 2008-07-24 Kai Pharmaceuticals, Inc. Modifications of peptide compositions to increase stability and delivery efficiency
NZ584048A (en) * 2007-10-02 2012-08-31 Marina Biotech Inc Lipopeptides for delivery of nucleic acids
WO2009075773A2 (en) 2007-12-07 2009-06-18 Goldstein Steven A Identification of toxin ligands
US20090318351A1 (en) * 2008-03-12 2009-12-24 Kevin Grimes Method of treating acute st-elevation myocardial infarction with a delta pkc antagonist
EP3539555B1 (en) 2009-07-29 2020-12-30 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels
LT2717896T (lt) * 2011-06-08 2017-02-27 Kai Pharmaceuticals, Inc. Terapiniai agentai, skirti fosforo koncentracijos serume reguliavimui
EP2776129B2 (en) 2011-11-10 2020-06-17 Kai Pharmaceuticals, Inc. Compositions for use in the treatment of chronic kidney disease-mineral bone disorder characterized by soft tissue calcification

Also Published As

Publication number Publication date
LUC00008I1 (enExample) 2017-03-16
FR17C1009I1 (enExample) 2017-04-21
US20250163103A1 (en) 2025-05-22
LT3192520T (lt) 2019-06-25
PT2459208T (pt) 2017-01-03
SMT201700014T1 (it) 2017-03-08
US20240116983A1 (en) 2024-04-11
BR112012002143B8 (pt) 2021-05-25
JP2013500990A (ja) 2013-01-10
WO2011014707A2 (en) 2011-02-03
FR17C1009I2 (fr) 2019-04-12
CN102711789A (zh) 2012-10-03
JP2013155195A (ja) 2013-08-15
CY2017010I1 (el) 2017-11-14
JP5764613B2 (ja) 2015-08-19
BR112012002143A2 (pt) 2016-11-08
US20160159860A1 (en) 2016-06-09
LTPA2017007I1 (lt) 2017-03-27
CN107674114A (zh) 2018-02-09
WO2011014707A3 (en) 2011-07-07
TW201116290A (en) 2011-05-16
EP3808363B1 (en) 2022-09-07
HRP20190923T1 (hr) 2019-10-04
TWI520744B (zh) 2016-02-11
NZ597922A (en) 2015-01-30
CN107674114B (zh) 2022-10-25
BR112012002143B1 (pt) 2020-12-08
ES2729051T3 (es) 2019-10-30
CA2769525A1 (en) 2011-02-03
CA2769525C (en) 2017-02-21
SG10201406921SA (en) 2014-11-27
CY1118388T1 (el) 2017-06-28
HRP20161614T1 (hr) 2017-02-24
US9701712B2 (en) 2017-07-11
EP4154900A1 (en) 2023-03-29
US20190194252A1 (en) 2019-06-27
SG178143A1 (en) 2012-03-29
RU2012107428A (ru) 2013-09-10
US10280198B2 (en) 2019-05-07
EP3539555B1 (en) 2020-12-30
EP3192520B1 (en) 2019-03-06
LT2459208T (lt) 2017-02-27
EP2459208A4 (en) 2014-06-04
HUE030960T2 (en) 2017-06-28
NO2017021I1 (no) 2017-05-05
US20180022777A1 (en) 2018-01-25
SI3192520T1 (sl) 2019-08-30
US8999932B2 (en) 2015-04-07
US20200399309A1 (en) 2020-12-24
US8377880B2 (en) 2013-02-19
SMT201700014B (it) 2017-03-08
KR101781841B1 (ko) 2017-09-26
LTC2459208I2 (lt) 2021-07-12
AU2010278897A1 (en) 2012-02-23
CN102711789B (zh) 2018-06-08
EP3808363A1 (en) 2021-04-21
RU2557654C2 (ru) 2015-07-27
SMT201900307T1 (it) 2019-07-11
PL3192520T3 (pl) 2019-08-30
PL2459208T3 (pl) 2017-05-31
KR20120104513A (ko) 2012-09-21
PT3192520T (pt) 2019-06-12
US9567370B2 (en) 2017-02-14
ES2607954T3 (es) 2017-04-04
HUE043838T2 (hu) 2019-09-30
LUC00008I2 (enExample) 2017-05-30
HK1167108A1 (zh) 2012-11-23
HUS1700008I1 (hu) 2017-04-28
US20150175664A1 (en) 2015-06-25
EP3539555A1 (en) 2019-09-18
EP4154900B1 (en) 2024-08-28
IL217749A (en) 2016-09-29
DK2459208T3 (en) 2017-01-23
CY1121922T1 (el) 2020-10-14
RU2557654C3 (ru) 2017-07-05
US20170114095A1 (en) 2017-04-27
EP2459208A2 (en) 2012-06-06
EP3192520A1 (en) 2017-07-19
AU2010278897B2 (en) 2015-02-26
DK3192520T3 (da) 2019-05-27
US20110028394A1 (en) 2011-02-03
IL217749A0 (en) 2012-03-29
US9278995B2 (en) 2016-03-08
US20130150297A1 (en) 2013-06-13
US20120178688A1 (en) 2012-07-12
JP2014094967A (ja) 2014-05-22
CY2017010I2 (el) 2017-11-14
JP5270799B2 (ja) 2013-08-21
EP2459208B1 (en) 2016-09-28
MX2012001213A (es) 2012-06-12
ZA201200726B (en) 2013-05-29

Similar Documents

Publication Publication Date Title
ZA201200726B (en) Therapeutic agents for reducing parathyroid hormone levels
GB0908957D0 (en) Therapeutic agents
ZA201209725B (en) Composition for improving sexual wellness
IL214919A0 (en) Method for therapeutic use
GB0900484D0 (en) Therapeutic agent
GB0910493D0 (en) Therapeutic agents
GB0906026D0 (en) Therapeutic compounds
GB0903949D0 (en) Therapeutic agents
GB0902450D0 (en) Therapeutic agents
GB0919824D0 (en) Therapeutic agents
GB0919825D0 (en) Therapeutic agents
GB0919829D0 (en) Therapeutic agents
GB0919820D0 (en) Therapeutic agents
GB0919819D0 (en) Therapeutic agents
GB0907971D0 (en) Therapeutic agents
GB0915586D0 (en) Therapeutic agents
GB0914533D0 (en) Therapeutic agents
GB0911965D0 (en) Therapeutic agents
GB0919821D0 (en) Therapeutic agents
GB201010582D0 (en) Therapeutic agents
GB201012100D0 (en) Therapeutic agents
GB201012101D0 (en) Therapeutic agents
GB201012102D0 (en) Therapeutic agents
GB201014963D0 (en) Therapeutic agents
GB201010583D0 (en) Therapeutic agents